Cite

    Baettig, F. et al. (2019). Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response. Journal for immunotherapy of cancer. 7 (1), p. . [Online].